Atherosclerotic complications account for increased morbidity and mortality in diabetic patients. Vascular smooth muscle cell (VSMC) transformation from quiescent contractile to synthetic proliferative phenotype is central to the evolution of atherosclerosis. Diabetic patients show increased propensity for VSMC migration and proliferation, a hallmark of SMC phenotypic de‐differentiation. Using specific pharmacological activators and inhibitors, we previously reported that augmented signaling via O‐linked N‐acetylglucosamine (O‐GlcNAc) transferase (OGT), the key enzyme catalyzing addition of O‐GlcNAc moieties to proteins, controls glucose‐induced VSMC proliferation. However, the mechanistic link between OGT and VSMC activation remains unknown. The goal of the current study was to investigate whether OGT plays a direct role in VSMC phenotypic transition. Using siRNA gene silencing in primary human aortic SMC (HASMC) cultures, we demonstrated that OGT deletion increased SM‐MHC and α‐SMA (SM contractile markers) expression concomitant to attenuated PCNA (proliferation marker) expression in response to high glucose in vitro, shown via immunoblotting and immunocytochemistry. Moreover, under glucose‐stimulated conditions, OGT knockdown decreased the expression of Cyclin E (cell cycle regulator) in OGT siRNA‐transfected HASMC vs. cells transfected with control siRNA. To interrogate the role of OGT in VSMC activation in vivo, we next developed the tamoxifen‐inducible VSMC‐specific OGT knockout mice by crossing OGTfl/fl female mice with tamoxifen‐inducible Myh11‐CreERT2 male mice; the resulting Cretg/OGTfl/Y male mice (produced in F1 generation) were used for Cre recombinase activation. Specifically, 6 wks old male mice were treated with tamoxifen (40 mg/Kg) or vehicle (peanut oil) i.p. once daily for 5 consecutive days. Aorta and heart were harvested from the mice 21 days after the last tamoxifen injection. Immunoblotting experiments confirmed loss of OGT expression in aortic vessels of tamoxifen‐treated Cretg/OGTfl/Y mice (smOGT−/Y) compared to vehicle‐treated Cretg/OGTfl/Y littermates and tamoxifen‐treated OGTfl/Y mice (smOGT+/Y, with intact OGT). In contrast, OGT expression remained unaffected in left ventricular tissue lysates derived from smOGT−/Y vs. smOGT+/Y mice, validating our SMC‐specific OGT knockout mouse model. Importantly, immunoblotting revealed increased SM‐MHC and α‐SMA expression in aortic vessels of smOGT−/Y mice compared to smOGT+/Y, with intact OGT; this increase in SM contractile marker expression was further accompanied with attenuated PCNA and IL1β (pro‐inflammatory marker) expression in smOGT−/Y mice. Together, these data demonstrate a direct role of OGT in VSMC phenotypic de‐differentiation. Our findings suggest a putative fundamental role of OGT in the etiology of diabetic vascular disease.Support or Funding InformationAHA‐Grant‐in‐Aid 16GRNT31200034; NIH‐NHLBI 1R56HL141409‐01This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Risks of vascular complications are enhanced two‐to‐four fold in diabetes, accounting for increased morbidity and mortality in these patients. Hyperglycemia is an important risk factor for macrovascular complications associated with diabetes. Diabetic patients exhibit an increased incidence of vascular smooth muscle cell (VSMC) migration and proliferation, a hallmark of VSMC phenotypic switching from the quiescent contractile state to a synthetic proliferative phenotype. Hyperglycemia increases glucose flux through the hexosamine biosynthetic pathway triggering an enhanced signaling via O‐linked N‐acetylglucosamine (O‐GlcNAc) transferase (OGT), the key enzyme catalyzing addition of O‐GlcNAc moieties to proteins. Protein O‐GlcNAcylation is a unique post‐translational protein modification implicated in diabetes and related cardiovascular complications. Previous studies have suggested both cardio‐protective and cardio‐detrimental effects of protein O‐GlcNAcylation in diabetes. However, the precise role of OGT in the etiology of diabetic atherogenesis remains incompletely understood. The goal of the current study was to investigate whether OGT modulates VSMC transition to a de‐differentiated phenotype under hyperglycemic conditions. Immunoblotting experiments revealed that in primary cultures of human aortic smooth muscle cells (HASMC) in vitro, benzyl 2‐deoxy α‐D‐galactopyranoside (BG), a pharmacological inhibitor of OGT, decreased high glucose‐induced OGT and O‐GlcNAc protein expression, and this was accompanied with attenuated PCNA (proliferation marker), reduced vimentin (SM synthetic marker) and increased SM‐MHC (SM contractile marker) expression. Consistent with these findings, deletion of OGT using siRNA gene silencing significantly lowered protein O‐GlcNAc and PCNA expression in glucose‐stimulated HASMC compared with glucose‐treated cells transfected with control siRNA. Notably, under glucose‐stimulated conditions, OGT knockdown enhanced calponin (SM contractile marker) expression in HASMC transfected with OGT siRNA vs cells transfected with control siRNA. Finally, electrophoretic mobility shift assay (EMSA) revealed that specific OGT inhibitors (BG and ST045849) attenuated high glucose‐induced DNA‐binding activity of YY1 and Elk1 (transcriptional repressors of SM contractile phenotype) in HASMC compared to cells treated with glucose alone. Taken together, these data clearly demonstrate that loss of OGT inhibits VSMC phenotypic de‐differentiation in response to hyperglycemia, suggesting OGT as a potential therapeutic target in diabetic atherosclerosis.Support or Funding InformationAmerican Heart Association ‐ Grant‐in‐Aid 16GRNT31200034This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.